Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Duke-NUS Medical School, Singapore, Singapore.
Nat Rev Dis Primers. 2018 Jun 28;4(1):3. doi: 10.1038/s41572-018-0002-y.
Influenza is an infectious respiratory disease that, in humans, is caused by influenza A and influenza B viruses. Typically characterized by annual seasonal epidemics, sporadic pandemic outbreaks involve influenza A virus strains of zoonotic origin. The WHO estimates that annual epidemics of influenza result in ~1 billion infections, 3–5 million cases of severe illness and 300,000–500,000 deaths. The severity of pandemic influenza depends on multiple factors, including the virulence of the pandemic virus strain and the level of pre-existing immunity. The most severe influenza pandemic, in 1918, resulted in >40 million deaths worldwide. Influenza vaccines are formulated every year to match the circulating strains, as they evolve antigenically owing to antigenic drift. Nevertheless, vaccine efficacy is not optimal and is dramatically low in the case of an antigenic mismatch between the vaccine and the circulating virus strain. Antiviral agents that target the influenza virus enzyme neuraminidase have been developed for prophylaxis and therapy. However, the use of these antivirals is still limited. Emerging approaches to combat influenza include the development of universal influenza virus vaccines that provide protection against antigenically distant influenza viruses, but these vaccines need to be tested in clinical trials to ascertain their effectiveness.
流感是一种传染性呼吸道疾病,在人类中,由甲型流感病毒和乙型流感病毒引起。通常以年度季节性流行的形式出现,偶发性大流行则涉及源自动物的甲型流感病毒株。世界卫生组织估计,每年的流感流行会导致约 10 亿人感染、300 万至 500 万人患严重疾病和 30 万至 50 万人死亡。大流行性流感的严重程度取决于多种因素,包括大流行病毒株的毒力和预先存在的免疫水平。1918 年发生的最严重流感大流行导致全球死亡人数超过 4000 万。流感疫苗每年都根据流行株进行配制,因为它们会因抗原漂移而在抗原上发生变化。然而,疫苗的效果并不理想,如果疫苗与流行病毒株之间存在抗原不匹配,疫苗的效果会显著降低。已经开发出针对流感病毒酶神经氨酸酶的抗病毒药物用于预防和治疗。然而,这些抗病毒药物的使用仍然受到限制。抗击流感的新兴方法包括开发通用流感疫苗,以提供针对抗原上差异较大的流感病毒的保护,但这些疫苗需要在临床试验中进行测试,以确定其有效性。